Table 4.
Five-year age-standardised net survival (ASNS) in men and women diagnosed with cancer in Spain in 2002–2007 and 2008–2013 and absolute change between periods.
| Cancer Group | Men | Women | ||||
|---|---|---|---|---|---|---|
| ASNS (95% CI), % | Absolute Change a (95% CI), % | ASNS (95% CI), % | Absolute Change a (95% CI), % | |||
| 2002–2007 | 2008–2013 | 2002–2007 | 2008–2013 | |||
| Oral cavity and pharynx | 37.4 (35.7, 39.1) | 38.2 (36.6, 39.9) | 0.9 (−1.5, 3.2) | 51.6 (48.7, 54.6) | 57.2 (54.4, 60.2) | 5.6 (1.5, 9.8) |
| Esophagus | 9.7 (8.6, 11.0) | 13.1 (11.6, 14.7) | 3.4 (1.4, 5.3) | 17.3 (13.8, 21.6) | 16.5 (13.1, 20.8) | −0.8 (−6.2, 4.6) |
| Stomach | 24.6 (23.5, 25.8) | 26.0 (24.8, 27.4) | 1.4 (−0.3, 3.2) | 30.6 (29.0, 32.3) | 30.3 (28.6, 32.2) | −0.3 (−2.8, 2.2) |
| Colon | 57.5 (56.5, 58.4) | 63.1 (62.2, 64.1) | 5.6 (4.3, 7.0) | 59.8 (58.7, 60.8) | 63.9 (62.8, 64.9) | 4.1 (2.6, 5.6) |
| Rectum | 55.8 (54.6, 57.1) | 60.4 (59.1, 61.7) | 4.6 (2.8, 6.4) | 58.1 (56.6, 59.7) | 62.7 (61.1, 64.3) | 4.6 (2.3, 6.8) |
| Liver | 15.2 (14.1, 16.3) | 17.9 (16.7, 19.2) | 2.8 (1.1, 4.4) | 16.4 (14.3, 18.7) | 16.2 (14.1, 18.6) | −0.2 (−3.4, 2.9) |
| Gallbladder and bile ducts | 18.7 (16.2, 21.6) | 22.3 (19.6, 25.3) | 3.6 (−0.3, 7.5) | 18.1 (15.7, 20.8) | 19.2 (16.5, 22.4) | 1.1 (−2.8, 5.0) |
| Pancreas | 5.7 (4.9, 6.6) | 7.2 (6.3, 8.2) | 1.5 (0.2, 2.8) | 7.3 (6.2, 8.5) | 10.0 (8.7, 11.4) | 2.7 (1.0, 4.5) |
| Larynx | 60.6 (58.8, 62.4) | 60.0 (58.0, 62.1) | −0.5 (−3.2, 2.2) | 68.5 (62.4, 75.1) | 66.1 (58.8, 74.2) | −2.4 (−12.4, 7.5) |
| Lung | 11.2 (10.7, 11.6) | 12.7 (12.2, 13.2) | 1.6 (0.9, 2.2) | 16.2 (15.1, 17.4) | 17.6 (16.5, 18.8) | 1.4 (−0.3, 3.0) |
| Skin melanoma | 79.1 (77.3, 81.0) | 82.3 (80.5, 84.1) | 3.2 (0.6, 5.7) | 88.6 (87.2, 90.0) | 88.9 (87.5, 90.3) | 0.3 (−1.7, 2.3) |
| Breast (women) | 83.2 (82.5, 83.9) | 85.5 (84.8, 86.2) | 2.3 (1.3, 3.3) | |||
| Cervix uteri | 64.4 (62.5, 66.3) | 65.5 (63.5, 67.5) | 1.1 (−1.7, 3.8) | |||
| Corpus uteri | 74.6 (73.4, 75.9) | 74.0 (72.8, 75.3) | −0.6 (−2.4, 1.1) | |||
| Ovary and annexes | 37.5 (36.0, 39.0) | 40.9 (39.3, 42.6) | 3.5 (1.2, 5.7) | |||
| Prostate | 87.8 (87.2, 88.4) | 89.6 (89.0, 90.1) | 1.7 (0.9, 2.6) | |||
| Testicle | 85.2 (81.0, 89.6) | 89.4 (85.2, 93.9) | 4.2 (−1.9, 10.3) | |||
| Kidney | 59.8 (58.1, 61.6) | 64.8 (63.0, 66.6) | 5.0 (2.4, 7.5) | 61.4 (59.1, 63.7) | 65.8 (63.7, 68.0) | 4.4 (1.3, 7.6) |
| Urinary bladder | 72.3 (71.5, 73.1) | 73.8 (73.0, 74.7) | 1.6 (0.4, 2.7) | 72.9 (71.1, 74.8) | 75.9 (74.2, 77.6) | 3.0 (0.5, 5.5) |
| Brain | 19.3 (17.8, 21.0) | 20.8 (19.2, 22.6) | 1.5 (−0.9, 3.9) | 21.2 (19.3, 23.2) | 24.2 (22.1, 26.5) | 3.1 (0.2, 6.0) |
| Thyroid | 78.3 (74.9, 81.8) | 86.1 (83.2, 89.1) | 7.8 (3.3, 12.3) | 88.8 (87.3, 90.3) | 93.1 (91.8, 94.4) | 4.3 (2.3, 6.3) |
| Hodgkin lymphoma | 80.0 (77.3, 82.7) | 80.6 (77.8, 83.4) | 0.6 (−3.3, 4.5) | 83.3 (80.8, 85.9) | 82.6 (80.0, 85.3) | −0.7 (−4.4, 3.0) |
| Non-Hodgkin lymphoma | 57.2 (55.4, 58.9) | 62.4 (60.7, 64.1) | 5.2 (2.8, 7.6) | 63.0 (61.4, 64.6) | 68.4 (66.8, 70.0) | 5.4 (3.2, 7.7) |
| Myeloma | 40.1 (37.7, 42.7) | 44.8 (42.2, 47.5) | 4.6 (1.0, 8.3) | 42.5 (40.0, 45.2) | 51.2 (48.5, 54.1) | 8.7 (4.9, 12.5) |
| Acute lymphoid leukemia | 35.1 (29.9, 41.3) | 41.6 (34.8, 49.6) | 6.5 (−2.9, 15.8) | 37.1 (30.4, 45.3) | 40.0 (32.1, 49.7) | 2.9 (−8.5, 14.3) |
| Chronic lymphoid leukemia | 78.8 (76.2, 81.5) | 77.7 (74.6, 80.8) | −1.1 (−5.2, 2.9) | 80.7 (77.7, 83.9) | 80.7 (77.7, 83.8) | −0.0 (−4.4, 4.3) |
| Acute myeloid leukemia | 17.0 (14.9, 19.4) | 19.2 (16.9, 21.8) | 2.2 (−1.1, 5.5) | 19.8 (17.3, 22.6) | 24.9 (22.1, 28.0) | 5.1 (1.2, 9.0) |
| Chronic myeloid leukemia | 59.2 (53.6, 65.3) | 68.8 (62.7, 75.4) | 9.6 (1.0, 18.2) | 67.5 (59.6, 76.5) | 73.0 (66.4, 80.3) | 5.5 (−5.4, 16.4) |
| Leukemia NOS and others | 42.5 (38.2, 47.2) | 45.9 (41.4, 50.9) | 3.4 (−3.1, 10.0) | 33.5 (28.5, 39.5) | 41.9 (36.1, 48.7) | 8.4 (0.0, 16.8) |
| All cancers b | 52.0 (51.7, 52.2) | 55.3 (55.0, 55.6) | 3.3 (3.0, 3.7) | 59.2 (58.9, 59.6) | 61.7 (61.4, 62.1) | 2.5 (2.0, 3.0) |
Abbreviations: NOS, not otherwise specified. a Absolute difference = ASNS 2nd period—ASNS 1st period. Bold identifies statistically significant changes. b Excluding non-melanoma skin cancer.